Diabetes Mellitus Type 2
Conditions
Brief summary
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of aleglitazar monotherapy in patients with Type 2 diabetes mellitus who are drug-naïve to anti-hyperglycemic therapy. Patients will be randomized to receive either aleglitazar 150 mcg orally daily or placebo for 26 weeks.
Interventions
DRUGaleglitazar
150 mcg orally daily
DRUGplacebo
matching aleglitazar placebo orally daily
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patient, \>/= 18 years of age * Diagnosis of Type 2 diabetes mellitus within 12 months prior to screening * Drug-naïve (defined as no anti-hyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months at any time in the past) * HbA1c \>/= 7% and \</= 9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit * Fasting plasma glucose \</= 13.3 mmol/L (\</= 240 mg/dL) at pre-randomization visit * Agreement to maintain diet and exercise habits implemented during the run-in phase during the full course of the study
Exclusion criteria
* Pregnant women, women intending to become pregnant during the study period, currently lactating women, or women of child-bearing potential not using highly effective, medically approved birth control methods * Diagnosis or history of: 1. Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes 2. Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months * Any previous treatment with thiazolidinedione or with a dual peroxisome proliferator activated receptor (PPAR) agonist * Any body weight lowering or lipoprotein-modifying therapy (e.g. fibrates) within 12 weeks prior to screening with the exception of stable (\>= 1 month) statin therapy * Prior intolerance to fibrate * Triglycerides (fasting) \> 4.5 mmol/L (\> 400 mg/dL) at screening or within 4 weeks prior to screening * Clinically apparent liver disease * Anemia at or within 4 weeks prior to screening * Inadequate renal function * Symptomatic congestive heart failure New York Heart Association (NYHA) Class II-IV at screening * Myocardial infarction, acute coronary syndrome or transient ischemic attack/stroke within 6 months prior to screening visit * Known macular edema at screening or prior to screening visit * Diagnosed and/or treated malignancy (except for basal cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) within the past 5 years * Uncontrolled hypertension * History of active substance abuse (including alcohol) within the past 2 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HbA1c | from baseline to Week 26 |
Secondary
| Measure | Time frame |
|---|---|
| Change in fasting plasma glucose (FPG) | from baseline to Week 26 |
| Responder rates, defined as target HbA1c: < 7.0%, < 6.5% at Week 26 | 26 weeks |
| Change in homeostatic index of insulin sensitivity (by Homeostasis Model Assessment for Insulin Sensitivity [HOMA-IS]) | from baseline to Week 26 |
| Change in lipids | from baseline to Week 26 |
| Change in markers of insulin sensitivity/cardiovascular risk | from baseline to Week 26 |
| Safety: Incidence of adverse events | approximately 30 weeks |
| Change in homeostatic index of beta cell function (by HOMA-BFC) | from baseline to Week 26 |
Countries
China, Hong Kong, Malaysia
Outcome results
None listed